The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.

[3] In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.

[4] In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of AstraZeneca) investigating combination treatments for cancer.

[12] This acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen.